ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is providing an update on the usage of the “at-the market” equity of its providing program.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Co. and Wainwright, LLC (collectively, the “Agents”), to carry out an “at-the market” equity offering system under which Acasti might issue as well as sell from time to time the everyday shares of its having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the end distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 million. The ATM Shares had been sold at prevailing market prices averaging US$1.0747 per share. No securities were marketed in the facilities of the TSXV or maybe, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a cash commission of 3.0 % on the aggregate yucky proceeds raised was paid to the Agents in connection with their services. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and superb as of March 5, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and will deliver the Company with extra flexibility in its continuous review process to enjoy as well as evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescription medications making use of OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical proof of safety and efficacy in lowering triglycerides in individuals with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being created for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements in this press release which are not statements of historical or current truth constitute “forward-looking information” to the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking assertions include known and unknown risks, uncertainties, along with other unknown variables that may cause the actual outcomes of Acasti to be materially different from historical outcomes and even from any later outcomes expressed or even implied by such forward looking statements. In addition to statements which explicitly describe such risks as well as uncertainties, people are actually urged to give some thought to statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or any other similar expressions to be forward-looking and uncertain. Readers are cautioned not to place undue reliance on these forward looking statements, which speak simply as of the day of this particular press release. Forward-looking assertions in this press release include, but are not limited to, info or statements about Acasti’s strategy, succeeding operations and its review of strategic alternatives.
The forward looking assertions found in this press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward Looking Statements” area found in Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com as well as on the investor aisle of Acasti’s website at www.acastipharma.com. Many forward-looking assertions in this press release are produced as of the day of this press release.
ACST Stock – Acasti doesn’t undertake to redesign any such forward looking statements whether as a direct result of information that is brand new , future events or even otherwise, except as required by law. The forward looking statements contained herein are also subject generally to risks and assumptions and uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities and The Canadian and exchange Commission securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is actually giving an update on the usage